Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development
Stefanie Enriquez‐geppert, Lisa Bevers, Arvid Rosander, Peter Fodran, Vince Polito
Biomolecules July 3, 2026 Peer reviewed DOI: 10.3390/biom16070983 via OpenAlex
Summary
Naturally derived psilocybin shows perceived therapeutic benefits across mental health domains, but the evidence for causal efficacy is mixed. Safety profiles are generally favorable but vary depending on the context, with potential risks for vulnerable populations. The review identifies significant gaps in research, including a lack of controlled trials and standardization efforts. A phased research roadmap is proposed to establish safety and integration into therapeutic systems.
Study at a glance
| Design | review |
|---|---|
| Key finding | Naturally derived psilocybin demonstrates perceived therapeutic benefits, yet evidence of causal efficacy remains mixed. |
Abstract
Naturally derived psilocybin is widely used, yet its therapeutic potential, pharmacological distinctiveness and regulatory feasibility remain understudied. This review evaluates the potential of naturally derived psilocybin using a six-criterion framework to evaluate: (1) therapeutic benefit, (2) safety and tolerability, (3) pharmacological uniqueness vs. synthetic psilocybin, (4) identity and composition control, (5) dose precision and stability, and (6) ecological sustainability. This paper answers three key questions about naturally derived psilocybin: Does it show therapeutic potential? Does it differ from synthetic psilocybin? Can it meet medicinal standards? Findings suggest perceived therapeutic benefits from naturally derived psilocybin across mental health domains, though evidence of causal efficacy is mixed. Safety profiles are favorable but context-dependent, with risks in vulnerable populations. Some preliminary preclinical evidence indicates possible entourage effects, but human validation is lacking. Dose precision varies, with purified psilocybin being most reliable, followed by standardized extracts, alcoholic, aqueous, and whole biomass preparations. Scalable cultivation is feasible but faces sustainability challenges. Key gaps include a lack of controlled trials, longitudinal safety evaluations, and standardization. We provide a phased research roadmap, which proposes short-term studies to establish safety, mid-term mechanistic and standardization efforts, and long-term integration into therapeutic, cultural, and ecological systems. This review highlights the promise of naturally derived psilocybin but underscores the need for rigorous evidence to support regulatory acceptance and clinical use.